Neurala Biosciences

Neuraly is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and fibrotic diseases. A subsidiary of D&D Pharmatech, the company leverages its expertise in GLP-1 receptor agonism to target neuroinflammation, a key driver of diseases like Parkinson's and Alzheimer's. Its lead candidate, NLY01, is a long-acting GLP-1R agonist designed to cross the blood-brain barrier and inhibit the activation of pathogenic microglia. Neuraly's pipeline also includes small molecule inhibitors targeting c-Abl for neurodegeneration and various compounds for fibrotic conditions. The company aims to provide disease-modifying therapies where current treatments only manage symptoms.